Eli Lilly plans to complete its application for FDA approval of tirzepatide in the coming weeks and expects regulatory action as early as later this year.
Amazon stock dips as uncertain cloud outlook overshadows revenue beat
Amazon reported first-quarter sales on Thursday that beat analysts’ estimates.
Meta shares pop 15% to 52-week high on guidance, sales increase
Meta reported first-quarter results that beat on the top and bottom lines, alongside stronger-than-expected guidance.
U.S. GDP rose at a 1.1% pace in the first quarter as signs build that the economy is slowing
Gross domestic product was expected to increase at an annualized pace of 2% in the first quarter, according to Dow Jones.
Stocks making the biggest moves premarket: Meta, Teladoc, Harley-Davidson, Southwest Airlines and more
These are some of the stocks posting the largest moves in early trading.
Here are Thursday’s biggest analyst calls: Apple, Meta, Amazon, Ford, Activision Blizzard & more
Here are the biggest calls on Wall Street on Thursday.
Musk met with Schumer and other lawmakers to discuss A.I. regulation
The meeting comes after Schumer recently launched an effort to develop a new framework to foster the technology while mitigating its biggest risks.
Wall Street worries GM will face a tougher 2023 than the automaker is letting on
Analysts say eroding pricing power, labor concerns and challenges in producing EVs will make it harder for GM to perform at the same profitability levels.
Il Makiage parent Oddity buys biotech startup Revela to design new molecules for beauty products
The company will use AI-based molecule discovery, a common tool in pharmaceutical drug development, to target cosmetics pain points like hair loss and aging.
Eli Lilly misses on earnings but raises full-year guidance
The company reported adjusted earnings of $1.62, which missed analyst expectations of $1.73 for the quarter.